Patient Guide: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 13 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06533761
Status: 🟢 Enrolling Now
Condition: AML, Adult, MDS
Phase: PHASE1

Where You Can Participate

This study is available at 13 locations across the country.

Top locations include:
  • • Duarte, California
  • • Aurora, Colorado
  • • Tampa, Florida
  • • And 10 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML - Join Clinical Trial NCTNCT06533761

How to Join This Clinical Trial - NCTNCT06533761

Learn how to participate in this PHASE1 trial studying an investigational therapy for AML, Adult, MDS. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with AML, Adult, MDS. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
AML, Adult, MDS
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06533761 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 13 locations. Find a study site near you:

Clinical Research Site

Duarte, California 91010 - United States

Status: RECRUITING

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: RECRUITING

Clinical Research Site

Tampa, Florida 33612 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02215 - United States

Status: RECRUITING

Clinical Research Site

St Louis, Missouri 63110 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10065 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

New York, New York 10065 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10466 - United States

Status: RECRUITING

Clinical Research Site

Cleveland, Ohio 44106 - United States

Status: RECRUITING

Clinical Research Site

Columbus, Ohio 43210 - United States

Status: RECRUITING

And 3 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for AML, Adult, MDS:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships